InSite Vision to Report First Quarter 2011 Financial Results on May 12, 2011

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB:INSV) announced today that it will report financial results for the first quarter ended March 31, 2011 on Thursday, May 12, 2011.

Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss first quarter 2011 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions during the call, or they can submit questions prior to the conference call via the company's website at www.insitevision.com through the "Information Request" tab on the Investor Relations page.

Analysts and investors can participate in the conference call by dialing 877-407-8035 for domestic callers and 201-689-8035 for international callers. A telephone replay will be available following the conclusion of the call by dialing 877-660-6853 for domestic callers and 201-678-7415 for international callers. All callers will need to enter the account number 286 and conference ID 372424.

The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing first quarter 2011 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.



CONTACT:

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
[email protected]
or
BCC Partners (Media and Investor Inquiries)
Karen L. Bergman, 650-575-1509
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Optical  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.